Feed KYMR
KY

Kymera Therapeutics

KYMR · NASDAQ

$109.30 +0.88% (+$0.95)
1M -5.31%
Market Cap $8.99B
P/E Ratio -
Div. Yield -
ROE 21.50%
Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Moderate
4/9
Valuation
13 /100
Expensive
P/B 5.96x
P/S 85.64x
EV/FFO N/A
Growth
22 /100
Declining
Book val. growth 47.71%
Rev. growth 5.75%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 285.41%
Op. margin 333.54%
FCF margin 226.65%
Quality
1 /100
Poor
ROE 21.50%
ROA 18.21%
Asset turnover 0.06x
Debt
69 /100
Low
Current ratio 9.83x
Int. coverage -1,420.20x
Debt/Equity 0.05x
Stability
27 /100
Unstable
Rev. volatility 56.79%
EPS volatility 19.39%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about KYMR
Online

About the company

Kymera Therapeutics is a U.S.-based biotechnology company that specializes in the development of therapeutics aimed at protein modulation using advanced protein degradation technologies. The company uses an innovative approach to treating diseases by focusing on selectively degrading faulty proteins in the body rather than blocking them. Kymera Therapeutics focuses on developing drugs for the treatment of oncology, immunology, and rare diseases, with its technology holding the potential to significantly change the way many serious health issues are treated.

Sector

Healthcare

Industry

Biotechnology

CEO

Nello Mainolfi

Employees

273

Headquarters

Watertown

Upcoming events

03 NOV

Earnings

Upcoming earnings report

25d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.